New CMV vaccine enters first human tests – could prevent dangerous infections

NCT ID NCT05089630

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-stage trial tests a new vaccine against cytomegalovirus (CMV), a common virus that can cause serious problems in newborns and people with weakened immune systems. The study involves 339 healthy adults aged 18 to 50, who will receive different doses of the vaccine or a placebo. The main goal is to check safety and how well the vaccine triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CMV vaccine (recombinant protein with adjuvant)
What this could lead to: If successful, this could lead to a vaccine that prevents cytomegalovirus (CMV) infection, which is especially dangerous for pregnant women and people with weak immune systems.
What could go wrong: This is an early first-in-human trial, so the vaccine may not trigger a strong enough immune response or could cause side effects. It is too soon to know if it will work in the real world.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Anaheim, California, 92806, United States
GSK Investigational Site

Long Beach, California, 90806, United States
GSK Investigational Site

Los Angeles, California, 90017, United States
GSK Investigational Site

Hallandale, Florida, 33009, United States
GSK Investigational Site

Miami, Florida, 33143, United States
GSK Investigational Site

Lexington, Kentucky, 40536-0084, United States
GSK Investigational Site

Dearborn, Michigan, 48127, United States
GSK Investigational Site

Springfield, Missouri, 65802, United States
GSK Investigational Site

Lincoln, Nebraska, 68510, United States
GSK Investigational Site

Omaha, Nebraska, 68134, United States
GSK Investigational Site

Las Vegas, Nevada, 89109, United States
GSK Investigational Site

Newark, New Jersey, 07103, United States
GSK Investigational Site

Secaucus, New Jersey, 07094, United States
GSK Investigational Site

New York, New York, 10065, United States
GSK Investigational Site

Austin, Texas, 78744-1645, United States
GSK Investigational Site

Cedar Park, Texas, 78613, United States
GSK Investigational Site

Galveston, Texas, 77573, United States
GSK Investigational Site

Puyallup, Washington, 98371, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.